COMPANY

SeaStar Medical

HQ: Denver, CO source · seastarmedical.com ↗ · Mountain

Location: Denver, CO · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Acute Kidney Injury Acute Kidney Injury Due to Sepsis Acute on Chronic Systolic Congestive Heart Failure Cardiorenal Syndrome Acute Renal Failure AKI ARDS COVID Continuous Renal Replacement Therapy Pulmonary Edema COVID-19 QUELIMMUNE (SCD-PED) C2Rx

$12.0MRaised (2 yrs)7Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $3.3M (Form D filed Oct 8, 2026). SEC Form D 0001831868-26-000002 (Oct 8, 2026)
Evidence (1 event)
- Oct 8, 2026 · SEC Form D 0001831868-26-000002
  Name of Issuer: SeaStar Medical Holding Corp; CIK: 1831868; Address: Denver, CO; Submission type: D; Filing date: 2026-10-08; Industry Group: Other Health Care; Date of First Sale: 2026-10-05; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3301572; Total Amount Sold: 3301572; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Oct 2, 2025 Trial start Not phased (device or behavioral study): Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD source ↗
Jun 20, 2025 Raise Follow-on offering: $8M (up to, as announced), announced Jun 20, 2025. Source: SEC filing. source ↗
Jun 20, 2025 Raise Follow-on offering: $4M (total, as published), announced Jun 20, 2025. Source: company release on GlobeNewswire. source ↗
Jul 19, 2024 Trial start —: QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry source ↗
Apr 17, 2023 Trial start Not phased (device or behavioral study): Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury source ↗
Sep 15, 2020 Trial start Not phased (device or behavioral study): C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19 source ↗
Sep 10, 2020 Trial start Not phased (device or behavioral study): Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections source ↗
2011-08 Trial start Not phased (device or behavioral study): Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury source ↗
2010-02 Trial start Not phased (device or behavioral study): Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Not phased · Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury · NCT05758077
2027-02 (ESTIMATED) · Not phased · Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD · NCT03836482

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $12.0M. Last 2 years.

Jun 20, 2025 Follow-on offering: $8M (up to, as announced), announced Jun 20, 2025. Source: SEC filing. source ↗
Jun 20, 2025 Follow-on offering: $4M (total, as published), announced Jun 20, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05758077	Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury	Not phased (device or behavioral study)	Recruiting	Apr 17, 2023	2026-12 (estimated)
NCT06517810	QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry	Not listed	Recruiting	Jul 19, 2024	2026-05 (estimated)
NCT03836482	Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD	Not phased (device or behavioral study)	Recruiting	Oct 2, 2025	2027-02 (estimated)
NCT01072682	Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure	Not phased (device or behavioral study)	Completed	2010-02	2011-05 (actual)
NCT04395911	Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections	Not phased (device or behavioral study)	Completed	Sep 10, 2020	Jul 5, 2021 (actual)
NCT01400893	Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury	Not phased (device or behavioral study)	Terminated	2011-08	2013-09 (actual)
NCT04537975	C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19	Not phased (device or behavioral study)	Withdrawn	Sep 15, 2020	Nov 15, 2020 (estimated)